Therefore, exploring the causes of cancer caused by BRCA1/2 mutation from the perspective of mechanism is significantly helpful to evaluate the clinical risk of BRCA1/2 mutation carriers, and also helps to provide different immunotherapy programs for different mutation patients. This evidence concerns the gene BRCA1 and cancer.